Literature DB >> 18417062

Optimal medical therapy with or without percutaneous coronary intervention for stable coronary disease: the COURAGE Study.

John A Farmer.   

Abstract

Entities:  

Year:  2008        PMID： 18417062

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  11 in total

1.  The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results.

Authors:  Whady Hueb; Paulo R Soares; Bernard J Gersh; Luiz A M César; Protásio L Luz; Luiz B Puig; Eulógio M Martinez; Sergio A Oliveira; José A F Ramires
Journal:  J Am Coll Cardiol       Date:  2004-05-19       Impact factor: 24.094

Review 2.  Clinical practice. Hypertriglyceridemia.

Authors:  John D Brunzell
Journal:  N Engl J Med       Date:  2007-09-06       Impact factor: 91.245

3.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

4.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.

Authors:  Shamir R Mehta; Christopher P Cannon; Keith A A Fox; Lars Wallentin; William E Boden; Rudolf Spacek; Petr Widimsky; Peter A McCullough; David Hunt; Eugene Braunwald; Salim Yusuf
Journal:  JAMA       Date:  2005-06-15       Impact factor: 56.272

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Myocardial infarction in the familial forms of hypertriglyceridemia.

Authors:  J D Brunzell; H G Schrott; A G Motulsky; E L Bierman
Journal:  Metabolism       Date:  1976-03       Impact factor: 8.694

7.  Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

Authors:  Hanna Bloomfield Rubins; Sander J Robins; Dorothea Collins; David B Nelson; Marshall B Elam; Ernst J Schaefer; Fred H Faas; James W Anderson
Journal:  Arch Intern Med       Date:  2002 Dec 9-23

8.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina.

Authors:  K A A Fox; P A Poole-Wilson; R A Henderson; T C Clayton; D A Chamberlain; T R D Shaw; D J Wheatley; S J Pocock
Journal:  Lancet       Date:  2002-09-07       Impact factor: 79.321

9.  Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia.

Authors:  J L Goldstein; H G Schrott; W R Hazzard; E L Bierman; A G Motulsky
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

10.  Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.

Authors:  J E Hokanson; M A Austin
Journal:  J Cardiovasc Risk       Date:  1996-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.